1. Background {#sec0001}
=============

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the second in females, with an estimated 1.4 million cases worldwide. In 2012 metastatic CRC (mCRC) was the cause of death in 693,900 patients [@bib0001], despite the advantages in screening, diagnosis and improved surgical and medical treatments.

About 20% of patients with CRC have already distant metastases at presentation [@bib0002] and totally 50% of patients with CRC will develop metastatic disease [@bib0003]. Moreover, a recent Norwegian study showed that 15.6% patients with CRC, who were considered surgically cured, had recurrent cancers including distant metastases during a five year follow up [@bib0004].

Today little is known about bone metastases (BM) from CRC. BM are considered frequent among patients with breast cancer, prostate cancer and lung cancer [@bib0005]. Bones are in fact the most frequent metastatic site among patients with breast cancer since up to 70% of all patients with disseminated breast cancer develop BM [@bib0006]. In breast, prostate and lung cancer, the antiresorptive treatment, bisphosphonates and denosumab, reduces further progression in bones and prevents complications by reducing the upregulated osteoclast activity caused by the metastasis. The outcome is fewer skeletal related events (SRE), and in the long term the antiresorptive treatment has an analgesic effect [@bib0007], [@bib0008], [@bib0009], [@bib0010].

Since the relative survival of CRC has increased over the recent decades [@bib0011], we expect to see an increasing number of patients in our clinical practice with BM from CRC. For that reason, basic knowledge of the incidence, possible risk factors, survival and treatment of BM from CRC is essential, hence this review was made.

2. Method {#sec0002}
=========

In order to systematically review the literature about BM from CRC we completed the following search in PubMed on the 24^th^ of September 2017 which resulted in 1064 hits: (((Bone AND metastases)) OR (\"Neoplasm Metastasis\"\[Mesh\] AND Bone)) OR ((\"Neoplasm Metastasis\"\[Mesh\]) AND (\"Bone and Bones\"\[Mesh\]))) OR \"bone metastases\") OR \"bone metastasis\")) AND ((((\"rectal cancer\") OR \"colon cancer\") OR \"colorectal cancer\") OR \"Colorectal Neoplasms\"\[Mesh\]). The following search was performed in EMBASE on 18th November 2017 resulting in 1374 hits: ((rectum cancer or rectum tumor or rectum carcinoma or colorectal cancer or colon carcinoma or colon tumor or colon cancer) and bone metastasis).

To ensure a complete search we also searched for "Metastatic pattern AND ((((\"rectal cancer\") OR \"colon cancer\") OR \"colorectal cancer\") OR \"Colorectal Neoplasms\"\[Mesh\])" in PubMed (1013 hits) and ((Rectum cancer or rectum tumor or rectum carcinoma or colorectal cancer or colon carcinoma or colon tumor or colon cancer) and metastatic pattern) in EMBASE (52 hits).

The searches were last updated 2nd July 2018.

Furthermore, we searched reference list of relevant studies.

We included human studies written in English describing patients with BM from CRC. The studies should include at least 10 patients with BM from CRC. Reviews, case stories and studies published before 1975 were excluded. In total 29 studies were identified through our search of the literature [@bib0012], [@bib0040].

The following information was extracted; incidence of BM, survival after BM diagnosis, treatment of BM and follow-up. If the authors did not display the incidence, we calculated it by dividing the number of patients with BM with the number of patients with CRC.

Furthermore, results of any statistical analysis regarding risk factors for developing BM, risk factors for poor survival after BM, and treatment efficacy were extracted.

3. Results and discussion {#sec0003}
=========================

We included 29 studies ([Table 1](#tbl0001){ref-type="table"}). One study was a randomized placebo controlled trial (RCT) [@bib0040], two were autopsy studies [@bib0038], [@bib0039], five were register studies [@bib0033], [@bib0037]. Twenty-one were retrospective cohort studies [@bib0012], [@bib0032]. Six studies included unselected cohorts of patients with CRC [@bib0012], [@bib0015], [@bib0033], [@bib0034]. The remaining studies included various cohorts of patients, for example cohorts only including patients with mCRC, CRC patients who underwent surgery, patients with adenocarcinoma or only rectal cancer patients [@bib0016], [@bib0032], [@bib0035], [@bib0036], [@bib0037], [@bib0038], [@bib0039], [@bib0040]. Furthermore, most studies did not report the exact follow-up period and those that did had different follow-up periods. This made a direct comparison across studies difficult and interpretation of results challenging.Table 1Studies included.Table 1AuthorYearCountryYearsPatientsNo. CRCNo. BMIncidence of BM (%)95% CI (%)Survival after BM diagnosisFollow up**Retrospective studies**All cases diagnosed with CRCSantini et al.\
2012\
Italy [@bib0012]1985-2009All cases with CRC\>2500264∼109.4 - 11.8Median 7 monthsNR -- all dead at last follow upPortales et al.\
2015\
France [@bib0013]1996-2006All cases with CRC24341104.53.7 -- 5.4Median 9.4 months-Bonnheim et al.\
1986\
USA [@bib0014]1970-1980All cases with CRC1406664.73.6 - 5.9Median 7 months-Zhenghong et al. 2017\
China \[[@bib0015]\]2006-2015All cases with CRC20661024.94.0 -- 6.0\--Selected patients with CRCLi et al. 2017\
China \[[@bib0016]\]\
Underwent radical surgery. T~any~N~any~M~0~1749502.92.2 - 3.8-5 yearsBaek et al\
2016\
South Korea \[[@bib0017]\]2007-2013Underwent surgery\
(including surgery for stage 4)5479631.20.9 - 1.5Median: 17.8Mean 19.6 monthsLan et al. 2015 Taiwan [@bib0018]2000-2010Underwent surgery (including surgery for stage 4)149220[a](#tb1fn1){ref-type="table-fn"}1.30.9 - 0.21-Median 69.7 monthsSun et al.\
2015\
China [@bib0019]2004-2009Underwent radical surgery (including surgery for stage 4)\
Adenocarcinoma\
No BM at primary surgery516316.04.1 - 8.4-Median 69.5 monthsJimi et al.\
2013\
Japan [@bib0020]1993-2008Underwent surgery\
(including surgery for stage 4)627243.82.5 - 5.6Median 6 months-Nozue et al.\
2002\
Japan [@bib0021]Not reportedUnderwent surgery\
(including surgery for stage 4)928121.31 - 2.2Median 5 months-Liu et al.\
2016\
China \[[@bib0022]\]2006-2014Underwent surgery\
(including surgery for stage 4)10,1322422.42.1 - 2.7Median 15.6 monthsMedian 21.1 monthsRoth et al.\
2009\
USA [@bib0023]2000-2008Only patients with CRC and a PET/CT252145.53.1 - 9.1Mean 15.9 monthsMean 38 monthsAmri et al.\
2015\
USA [@bib0024]2004-2011CC -- patients with single segment resection\*\*974-Right colon: 1.4\
Left colon:\
0\
Sigmoid: 1.9\
\--Median\
Right colon: 42 months\
Left colon:\
45 months\
Sigmoid:\
45 months\
Chiang et al.\
2014\
Taiwan [@bib0025]2002-2006RC; T3/T4 - underwent surgery M0; No preoperative radiation or chemotherapy884515.84.3 - 7.5-Mean 77.8 monthsAll cases with mCRCPatanaphan et al.\
1993\
USA [@bib0026]1979-1982mCRC1631173.4 - 11.8Median 10 months-Besbeas et al.\
1977\
USA [@bib0027]1960-1970\
mCRC765536.95.2 - 8.9Mean 13.2 months-Selected patients with mCRCSundemeyer et al.\
2005\
USA [@bib0028]1993-2002mCRC; adenocarcinoma102010610.48.6 - 12.4Median 21 months-Holch et al.\
2017\
Germany \[[@bib0029]\]2007-2014mCRC, adenocarcinoma, received treatment385\-\-\--Until diagnosis of mCRCYeager et al.\
2015\
USA [@bib0030]2008-2012mCRC - genotyped tumors91813014.212.1 -16.6\--Kemeny et al\
2014\
USA [@bib0031]2003-2\[27\]013mCRC -- treated with liver resection, HAI and systemic chemotherapy. available KRAS data169-KRAS WT 2\
KRAS MUT 13.4\--Median\
44.3 monthsChristensen et al.\
2018\
Denmark [@bib0032]2005 - 2008mCRC treated with cetuximab and irinotecan as third line treatment4806513.510.7 - 16.9-Median 25.2 months**Register studies**Kanthan et al.\
1999\
Canada [@bib0033]1970-1995All cases with CRC53523556.66 - 7.35-year survival: 16 -- 38 %[b](#tb1fn2){ref-type="table-fn"}-Riihimäki et al. 2016\
Sweden [@bib0034]2002-2012All cases with CRC49,09613982.92.7 - 3.0Median 5.5 months[c](#tb1fn3){ref-type="table-fn"}-Qui et al.\
2015\
USA [@bib0035]2010-2011All cases with CRC, adenocarcinoma46,0273560.80.7 - 0.91-year survival 36.2 %Only at time of diagnosis of CRCVan Gestel et al. 2014\
Nederlands [@bib0036]2003-2008CRC; T~any~N~any~M~0~ and underwent surgery56711573.02.4 - 3.2-Median 5.0 years -- only sites at diagnosis of mCRC included.Khattak et al.\
2012\
Australia [@bib0037]2006-2011mCRC -- only single site metastases1207322.71.8 - 3.7Median 5.1 months-**Autopsy studies**Hugen et al.\
2014\
Netherlands [@bib0038]1991-2010Autopsy, CRC58171031.7\-\--Katoh et al.\
1995\
Japan [@bib0039]1970-1987Clinical and autopsy reports1182823.716.4 - 32.4\--**Randomized study**Heras\
2007\
Greece [@bib0040]-mCRC, BM7373\-\-\--[^1][^2][^3][^4]

3.1. Incidence of BM {#sec0004}
--------------------

Twenty-seven of the studies reported an incidence of BM among their patients. The incidence of BM among the various subpopulations of CRC patients is presented in [Table 1](#tbl0001){ref-type="table"}.

The incidence of BM in unselected patients with CRC was described in three retrospective cohort studies [@bib0013], [@bib0015] and two large register studies [@bib0033], [@bib0034] and ranged from 2.9% to 6.6%. The distribution of stage and exact follow-up period in these studies were not accounted for. A sixth study followed all patients until death, but unfortunately, they did not provide an exact incidence. However, they stated that 264 patients among more than 2500 patients developed BM giving an incidence around 10% [@bib0012]. As expected a higher incidence of BM was generally found when only including patients with mCRC. Two cohort studies described an incidence of BM of 7% and 6.9% among these patients \[[@bib0026],[@bib0027]\] and the register study by Riihimaki et al. reported an incidence of 9.3% [@bib0034] A fourth study presented an incidence of 10.4% in a population of patients with mCRC adenocarcinoma [@bib0028]. Most of the studies might have underestimated the true incidence. Firstly, most studies did not report the exact follow-up period, and only one study reported that they followed patients until death. Secondly, all studies were retrospective or register based and mostly based on routine follow-up schemes, which not necessarily would capture asymptomatic BM.

Two autopsy studies also presented an incidence of BM among patients with CRC ranging from 1.7% in a study by Hugen et al. [@bib0038] to 23% in a study by Katoh et al. [@bib0039]. However, in both studies there was a potential heavy selection bias since autopsies were not described as being performed on all patients but only after request from doctors or patients. Therefore, these results should be interpreted with caution.

It has been suggested that the incidence of BM from CRC is increasing due to better diagnostics options and CRC patients living longer, but so far this has remained as speculations. In this review we were not able to assess if the incidence varied over time, due to differences in patient populations and overlap in time periods for data collection in the included studies.

3.2. Risk factors for BM {#sec0005}
------------------------

Fifteen studies described a statistical analysis of potential risk factors for BM \[[@bib0012],[@bib0015],[@bib0016],[@bib0018],[@bib0019],[@bib0022],[@bib0025],[@bib0028],[@bib0030]--[@bib0032],[@bib0034],[@bib0035],[@bib0038],[@bib0039]\]. Summary of their results is presented in [Table 2](#tbl0002){ref-type="table"}. All studies were retrospective and they described different cohorts making comparison of the results difficult.Table 2Risk factors for bone metastases.Table 2AuthorType of analysis[a](#tb2fn1){ref-type="table-fn"}Factors associated with increased risk of bone metastasesOther variable included in analysis but no association with bone metastases identifiedSantini et al. [@bib0012]Univariate Kaplan Meier estimate among (only including patients with BM)Primary tumor grade (Poor grade).Primary tumor site,\
Primary tumor stage,\
Primary tumor histology,\
Lymph node status,\
Use of adjuvant chemotherapy.Zhenghong et al. [@bib0015]Multivariate logistic regressionRectal cancer,\
Lung metastases,\
CEA \> 5µg/l.\
Gender,\
Primary tumor histology,\
Primary tumor stage,\
Initial treatment,\
Liver metastases.Li et al. [@bib0016]Multivariate logistic regressionRectal cancer,\
Lymph node met. at primary CRC surgery,\
Metachronous lung met.Age,\
Gender,\
Primary tumor histology,\
Primary tumor stage,\
CA199.Lan et al. [@bib0018]Univariate Chi Square TestNone.RAS mutation status,\
PIK3CA mutation status.Sun et al. [@bib0019]Multivariate logistic regressionRectal cancer,\
Lymph node met. at primary CRC surgery.Age,\
Gender,\
Albumin level,\
Hemoglobin,\
CEA,\
Transfusion,\
Primary tumor size,\
Primary tumor grade,\
Primary tumor stage,\
Primary tumor Invasion,\
Metastasis at diagnosis of CRC.Liu et al. [@bib0022]Univariate Chi Square testRectal cancer,\
Male.Age,\
Primary tumor grade,\
Tumor histology.Chiang et al. [@bib0025]Univariate Kaplan Meier estimateMiddle and distal as opposed to proximal rectal cancer.None.Sundemeyer et al. [@bib0028]Multivariate logistic regressionRectal cancer,\
High number of systemic therapies,\
Lung metastases,\
Early stage disease,\
No liver metastases.Peritoneal metastases,\
Adjuvant/neoadjuvant therapy.Yeager et al. [@bib0030]Univariate competing regression model[b](#tb2fn2){ref-type="table-fn"}Rectal cancer,\
RAS mutation,\
Lung metastases,\
Metastases at diagnosis of CRC.Surgery.Kemeny et al. [@bib0031]Univariate cumulative incidence functionKRAS mutation.None.Christensen et al. [@bib0032]Univariate cox regressionNone.Primary tumor location,\
Age,\
Gender,\
RAS mutation,\
BRAF mutation,\
PIK3CA mutation.Riihimäki et al. [@bib0034]Multivariate logistic regressionRectal cancer.\
[- Colon cancer patients:]{.ul}\
Male,\
Low age,\
Distal opposed to proximal colon.\
[- Rectal cancer patients:]{.ul}\
Low age.[- Colon cancer patients:]{.ul}\
Tumor histology\
[- Rectal cancer patients:]{.ul}\
Tumor histology,\
GenderQui et al. [@bib0035]Univariate Chi Square testRectal cancer,\
Lung metastases,\
Liver metastases.None.Hugen et al. [@bib0038]Univariate chi square testSignet-ring cell carcinoma.Primary tumor location.Katoh et al. [@bib0039]Univariate chi square and fisher exact testSignet-ring cell carcinoma,\
Liver metastases,\
Lung metastases.Primary tumor location,\
Primary tumor grade.[^5][^6][^7]

### 3.2.1. Primary tumor location {#sec0006}

From the studies included in this review it seems likely that location of primary tumor affects the likelihood of BM, with an increasing risk of BM the more distal the tumor is located.

Eight out of twelve studies that compared the risk of BM among rectal and colon cancer patients \[[@bib0016],[@bib0019],[@bib0022],[@bib0025],[@bib0028],[@bib0030],[@bib0034],[@bib0035]\] identified an increased risk among patients with rectal cancer, and none of the four remaining reported the reverse association \[[@bib0012],[@bib0032],[@bib0038],[@bib0039]\]. Five studies presented results of multivariable analysis and in all studies rectal cancer was identified as an independent risk factor for BM \[[@bib0015],[@bib0016],[@bib0019],[@bib0022],[@bib0034]\]. The OR for BM among patients with rectal cancer compared to colon cancer was on multivariable analysis 1.5 (CI 95% = 1.4--1.7) in a large register study by Riihimäki et al. [@bib0034], and between 2.0 and 2.4 in three retrospective cohort studies \[[@bib0015],[@bib0019],[@bib0022]\]. Sundermeyer et al. did only report p values from their multivariable analysis [@bib0028].

The specific location colon or rectum might also affect the risk of BM. A study by Chiang et al. which only included patients with rectal cancer, identified an increased incidence of BM in distal rectum (11.11%), compared to the middle rectum (6.95%) and in the proximal rectum (3.44%) (p \< 0.001) [@bib0025]. A similar result among colon cancer patients was observed by Riihimäki et al. [@bib0034]. They identified an OR for developing BM of 1.2 (CI 95% = 1.1--1.4) for patients with distal colon cancer opposed to proximal cancer.

A potential bias of the result could be that direct invasion of the bone was included as bone metastases, none of the studies reported that they excluded direct invasion in their analysis. The pattern of metastases could be explained by Batson\'s venous plexus, a network of valveless veins that connect the deep pelvic and thoracic veins to the internal vertebral venous system \[[@bib0020],[@bib0030],[@bib0039],[@bib0041]\].

### 3.2.2. Primary tumor stage {#sec0007}

No firm conclusions can be made regarding potential association between primary tumor stage and risk of BM. A study by Sundemeyer et al. conducted on mCRC patients, found a significant association between incidence of BM and early stage cancer on multivariable analysis [@bib0028].

Oppositely, Sun et al. and Zhenghong et al. identified a significantly increasing incidence of BM with increasing stage in univariate but not multivariate analysis. Both also included patients with CRC who did not developed metastases, and therefore the association found on univariate analysis most likely reflects the increased risk of all metastases in higher stages \[[@bib0015],[@bib0019]\]. Oppositely, two cohort studies found no association \[[@bib0012],[@bib0016]\].

### 3.2.3. Histological type of CRC and mutation status {#sec0008}

Results regarding primary tumor grade (well differentiated, moderately differentiated, poorly differentiated or undifferentiated) and risk of BM is inconclusive. Four studies of which three were conducted on selected cohorts, including one autopsy study, found no association \[[@bib0019],[@bib0022],[@bib0039]\]. However, a study by Santini et al. including 269 patients with BM found an association with poor differentiated tumors having the shortest time (6 months) to BM and well differentiated the longest (33 months). They did not include undifferentiated tumors in analysis [@bib0012]. The association between poorly differentiated tumor and BM are also observed in other tumor types e.g. gastric cancer has shown a relationship between poorly differentiated tumors and BM [@bib0042].

Signet-ring cell carcinoma seems to be associated with increased likelihood of BM though it is not well investigated. Whereas the other histological subtypes have not been found to affect likelihood of BM. Six studies performed a statistical analysis of the association between BM and histological types of CRC. The autopsy studies by Katoh et al. and Hugen et al. were the only two studies that performed separate analysis for signet-ring cell carcinoma compared to the other types. Both studies observed that signet-ring cell carcinoma showed a significantly higher incidence of BM than mucinous adenocarcinoma and adenocarcinoma [@bib0038], [@bib0039].

The remaining four studies only compared adenocarcinoma to mucinous adenocarcinoma or adenocarcinoma to mucinous adenocarcinoma and signet ring carcinoma combined. None of the four found a significant association with risk of BM [@bib0012], [@bib0016], [@bib0022], [@bib0034].

A hypothesis is that different molecular patterns of the cancer explain the pattern of metastases. Thus, genetic alterations in the tumor could possibly increase the ability of the tumor to seed certain organs such as the bone, brain or lung. *RAS* mutations are established predictors of poor response to anti-EGFR therapy and are associated with aggressive tumor biology [@bib0031], [@bib0043], [@bib0044]. *PIK3CA, BRAF*, and *RAS* mutations are the only mutations having been assessed for association with BM development. Only *RAS* mutations have been found to be a potential risk factor, though evidence is low and data conflicting.

Four studies have looked at whether *RAS* mutations (*KRAS* and *NRAS)* are associated with BM. All studies were conducted on selected and not comparable cohorts and the results were therefore hard to compare [@bib0018], [@bib0030], [@bib0032]. The study by Yaeger et al. was the largest of the four, and conducted on unselected mCRC patients as opposed to the three others. They identified a significant association on multivariable analysis between *RAS* mutation and BM with a hazard ratio (HR) of 1.62 (CI 95% = 1.1--2.3) [@bib0030]. However, *RAS* mutation status was used to guide anti-EGFR therapy which could be a potential confounder for the association between *RAS* and BM development [@bib0045]. Kemeny et al. only included *KRAS* exon 2 mutation but also identified a significantly higher cumulative incidence of BM among mutated compared to wild type in univariate analysis [@bib0031].

The two remaining studies did not find a significant association between *RAS* mutation and BM. However, one only included metastases at diagnosis of metastatic disease [@bib0018], and the other was conducted on a selected cohort of patients who all received the same third line treatment which might have confounded a potential association [@bib0032].

The association between *RAS* mutation and BM could be due to different gene expression and protein activations in cells with *RAS* mutation compared to *RAS* wildtype cells [@bib0045]. Another explanation could be changes in exosome composition. The exosome protein expression, including integrin expression, is markedly different between *RAS* wildtype and *RAS* mutant colon cancer cells [@bib0046], and studies have shown exosomal protein expression pattern to be important for organ-specific metastasis by directing creation of premetastatic niches [@bib0047]. Especially exosomal integrin was reported to have a crucial role in directing metastases to the bone [@bib0048].

### 3.2.4. Metastases at other sites {#sec0009}

Having lymph node metastases at primary surgery and lung metastases at any time are identified as potential risk factors for developing BM. For liver metastases the results were inconclusive.

Having lymph node metastases at primary tumor surgery were statistically significant associated with increased risk of later development of BM in two studies, that both only included patients who underwent radical surgery \[[@bib0016],[@bib0019]\]. Sun et al. identified an OR of 2.0 (CI 95% = 1.3--3.1) in multivariable analysis [@bib0019], and likewise Li et al. found a comparable OR of 2.3 (CI 95% = 1.3--4.1) [@bib0016]. Santini et al. found that patients who were lymph node positive at primary surgery had a median time to BM of only 13 months compared to 20 months among lymph node negative patients. However, the association was not statistically significant [@bib0012]. None of the above mentioned studies assessed whether lymph node involvement specifically increases the risk of BM or the association just reflects the association between lymph node status and increased risk of distant metastases. No studies have looked at the effect on lymph node metastases developed after primary surgery.

Six studies (including one autopsy study, one register study, and three retrospective cohort studies) looked at the association between bone metastases and lung metastases and all found a significantly increased likelihood of BM \[[@bib0015],[@bib0016],[@bib0028],[@bib0030], [@bib0035],[@bib0039]\]. Two of the retrospective cohort studies presented results of multivariable analysis and identified an OR of 2.5--4.8 of BM for patients having lung metastases \[[@bib0015],[@bib0016]\]. The remaining studies only performed univariate analysis and found a 2--3 fold increase in incidence of BM among patients who had lung metastases compared to those who did not \[[@bib0028],[@bib0030],[@bib0035],[@bib0039]\]. However, a causal relationship is hard to determine, since none of the studies demanded lung metastases to have been diagnosed before BM. Thus, several studies suggest that patients with rectal primaries are more likely than patients with colon primaries to present with lung metastases \[[@bib0049],[@bib0050]\].

Four not comparable studies have looked at potential associations between liver metastases and BM with opposite results. Katoh et al. did in their autopsy study show a significantly increased prevalence of liver metastases among patients with BM compared to patients without BM [@bib0039]. Qui et al., who only included metastases at primary diagnosis, found a significant increased incidence of BM at diagnosis of CRC in patients who also had liver metastases compared to mCRC patients without liver metastases [@bib0035]. Oppositely, Sundemeyer et al. found a significant decreased incidence of BM among patients with liver metastases compared to patients without in a cohort of mCRC patients [@bib0028]. Lastly, univariate analysis revealed that liver metastases were not associated with BM in the study by Zhenghong et al. [@bib0015].

### 3.2.5. Gender {#sec0010}

Male gender might be associated with increased risk of BM, although results are not conclusive. A large cohort study by Liu demonstrated a significantly higher incidence of BM among male CRC patients compared to female in univariate analysis [@bib0022]. Unfortunately, they did not adjust for location of primary tumor, which might bias the result. Male patients have increased incidence of rectum cancer compared to female patients [@bib0034], and the association between gender and BM might therefor be explained by this. More convincing, Riihimäki et al. demonstrated a significantly increased risk for BM for males compared to females among colon cancer patient in a large register study. This association remained significant when they adjusted for specific location in the colon. However, they did not find a significant association among rectal cancer patients [@bib0034]. Four smaller cohort studies, including a study conducted by our group, did not demonstrate any association \[[@bib0015],[@bib0016],[@bib0019],[@bib0032]\].

This finding is in contrast with a recent review which concluded that for lung cancer females might have a more favorable bone microenvironment for metastasis formation [@bib0051]. Anyhow, the differences could possibly be the result of statistical variation.

### 3.2.6. Age of patients {#sec0011}

Age might influence on the risk of developing BM, however, results are not conclusive. Low age (\<60 years) was found to be associated with a significantly higher incidence of BM in the register study by Riihimäki et al. [@bib0034]. Among patients with colon cancer, patients older than 79 years had an odds ratio (OR) for developing BM of 0.4 (CI 95% = 0.3--0.6) compared to patients younger than 60 years. Among rectal cancer patients the OR was 0.3 (CI 95% = 0.2--0.4). Four smaller cohort studies did not find any association \[[@bib0016],[@bib0019],[@bib0022],[@bib0032]\].

The young age could reflect a more aggressive disease in younger patients which leads to BM development [@bib0052] or it could be a consequence of older patients with several comorbidities did not receive treatment and, thus, had fewer evaluations and short OS [@bib0053].

### 3.2.7. Systemic therapies {#sec0012}

The impact of systemic anticancer therapy on risk of BM among patients with CRC is not well investigated, and again firm conclusions cannot be drawn. Only the study by Sundemeyer et al. investigated the potential association between systemic therapies received in the metastatic setting and incidence of BM and found a significant association with high number of systemic therapies, as well as therapy with irinotecan and oxaliplatin compared to patients not receiving these therapies [@bib0028]. Two studies, including the one by Sundemeyer et al., looked at whether adjuvant/neoadjuvant therapy affected the likelihood of BM but neither found an association \[[@bib0012],[@bib0028]\].

### 3.2.8. Survival {#sec0013}

Survival after BM was mentioned in 16 studies. Median overall survival (OS) after diagnosis of BM ranged from 5 to 21 months ([Table 1](#tbl0001){ref-type="table"}).

Median overall survival (OS) after diagnosis of BM ranged from 5 to 21 months ([Table 1](#tbl0001){ref-type="table"}). However, due to the difference in time period patients received treatment and different cohorts, a direct comparison was difficult to make. In the studies that included all patients with CRC and BM the median OS after BM diagnoses ranged from 7 to 9.4 months \[[@bib0012]--[@bib0014]\]. The two register studies by Khattak et al. and Riihimäki et al. reported a median OS after diagnosis of metastatic disease in patients who only had BM. They found a median OS of 5.1 [@bib0037] and 5.5 months [@bib0034].

Several studies looked at the prognosis for patients with BM compared to patients with other metastases. The results in this regard are contradictory. The two register studies by Khattak et al. and Riihimäki et al. observed that mCRC patients with BM only, had significantly worse survival than patients with single site metastases at other sites such as liver and lung \[[@bib0034],[@bib0037]\]. Likewise, Qui et al. did in their large register study find a 1 year cause specific survival of 29.6% for patients with BM only compared with 60.2% among patients with liver only and 36.2% among patients with lung only metastases [@bib0035]. Oppositely, three studies found a better prognosis for patients with BM only compared to patients with both BM and visceral metastases \[[@bib0014],[@bib0022],[@bib0033]\].

Five studies presented statistical analysis of factors associated with poor survival after diagnosis of BM. Summary of their results are found in [Table 3](#tbl0003){ref-type="table"}. Several variables were associated with poor survival including: osteolytic lesions, more than one bone lesion, rib metastases, elevated CEA, other metastases, lung metastases and BM at diagnosis of CRC \[[@bib0012],[@bib0017],[@bib0020],[@bib0022],[@bib0035]\]. However, the studies were differently designed and used different cohorts making a comparison difficult. Furthermore, the studies all included different variables and only a few variables were included in analyses in more than one study. Therefore, the above mentioned results should be interpreted with caution, and new studies are needed to confirm a potential association.Table 3Factors associated with poor survival after bone metastases diagnosisTable 3AuthorType of analysis[a](#tb3fn1){ref-type="table-fn"}Factors associated with short survival after bone metastasesOther variable included in analysis but no association with survival after bone metastasesSantini et al. [@bib0012]Univariate log-rank testOsteolytic lesions,\
2 or more bone lesions.SRE,\
Bisphosphanate treatment.Se-Jin Baek et al. [@bib0017]Multivariable cox regression analysisBoneM from colon cancer,\
Initial bone metastases.SRE,\
Age,\
Gender,\
Body mass index.Jimi et al. [@bib0020]Multivariable cox regression analysisLung metastases,\
Rib metastases.Site of primary cancer,\
Age,\
Gender,\
Liver metastases,\
Vertebral metastases,\
Pelvic metastases,\
CEA.Liu et al. [@bib0022]Multivariable cox regression analysisElevated CEA,\
Other metastases at BoneM diagnosis.Tumor differentiation,\
Lymphatic metastasis,\
Perineural invasion,\
Alkaline fosfatase,\
Systemic chemotherapy,\
Radiotherapy,\
Bisphosfanate therapy.Qui et al. [@bib0035]Univariate log-rank testNone.Lung metastases,\
Liver metastases.[^8][^9]

3.3. Treatment {#sec0014}
--------------

Eight studies described treatment of BM. Treatments used for BM included bisphosphonate therapy, systemic chemotherapy, radiotherapy, surgery and medical pain relief \[[@bib0012],[@bib0014],[@bib0019]--[@bib0022],[@bib0040],[@bib0054]\]. However, only three studies analyzed the effect of different treatments (bisphosphonate, radiotherapy and chemotherapy), including two retrospective cohort studies \[[@bib0012],[@bib0022]\] and one small randomized study [@bib0040]. Summary of the three studies are presented in [Table 4](#tbl0004){ref-type="table"}.Table 4Treatment of bone metastasesTable 4AuthorEnd point regarding treatment efficacyTreatment of BoneM and comparison (patients in group)ResultsSantini et al. [@bib0012]Time to first SRE,\
OS.Zoledronic acid (126) vs no bisphosphonate therapy (31)Time to first SRE: Significantly longer time for Zolodronic acid vs no bisphosphonate therapy (2 months vs1 months, *p* = 0.009).\
OS: NS.Liu et al. [@bib0022]OS.Bisphosphonate (108) vs. no bisphosphonate (134),\
Radiation therapy (172) vs no radiation therapy (70),\
Chemotherapy (171) vs no chemotherapy (71),\
Combination therapy (192) vs single therapy (38).[Univariate analysis]{.ul}\
Bisphosphonate treatment: NS,\
Radiation therapy: NS,\
Chemotherapy: Significantly (*p* = 0.012) associated with better OS[a](#tb4fn1){ref-type="table-fn"},\
Combination therapy: Significantly (p = 0.01) associated with better OS[a](#tb4fn1){ref-type="table-fn"}\
[Multivariate analysis]{.ul}\
Chemotherapy: NS.Heras et al. [@bib0040][Primary endpoint:]{.ul}\
Proportion with SRE.\
[Secondary endpoint:]{.ul}\
time to SRE,\
events per year,\
time to progression of bone lesion.Ibandronate treatment vs placebo.Ibandronate significantly superior to placebo regarding:\
Proportion with SRE (39 % vs. 78 %, *p* = 0.019),\
Time to first SRE (214 days vs 81 days, p = 0.009),\
SRE per year (2.36 vs 3.14, *p*  = 0.018),\
Time to progression of bone lesion (214 days vs 81 days, *p* = 0.018).[^10][^11]

Bisphosphonate efficacy was statistically evaluated in all three studies \[[@bib0012],[@bib0022],[@bib0040]\]. The randomized study was a small pilot study and had several methodological short comings. Firstly, placebo treatment and randomization were not described. Secondly, no predefined protocol was described. Thirdly, no comparison of baseline characteristics was presented between treatment and placebo group and they did not perform any statistical adjustment for other factors which could have affected treatment outcome [@bib0040]. The incidence of adverse events was described as comparable to placebo but no analyses was presented [@bib0040]. The retrospective studies also had several shortcomings besides the retrospective nature of the study. In both studies patients received other therapies than bisphosphonate for bone metastases during study period, and neither study did statistically adjust for other factors \[[@bib0012],[@bib0022]\].

Though the level of evidence is not high, the studies indicate that bisphosphonate treatment might improve outcome with regard to skeletal-related events (SRE) (defined as pathologic fracture, spinal cord compression, radiation therapy to bone, change in antineoplastic therapy and surgery to bone), but not overall survival. No study has evaluated denosumab in CRC.

This conclusion is consistent with studies on effect of antiresorptive treatment for BM in lung, breast and prostate cancer, where it has been shown to reduce skeletal related events (SRE) \[[@bib0007]--[@bib0010]\].

The effect of other therapies for BM from CRC is poorly investigated. Only the effect of systemic chemotherapy and radiotherapy has been analyzed with regard to OS after BM diagnosis, and this was only in one retrospective cohort study [@bib0022]. Systemic chemotherapy was found to improve survival among BM patients in univariate analysis. However, most patients also had visceral metastases and the improved survival might as well be related to the treatment effect on these, indicated by subgroup analyses of patients with BM as only metastatic site where no survival benefit was identified. Furthermore, no association was identified in multivariable survival analysis [@bib0022].

3.4. Limitations {#sec0015}
----------------

This study had some limitations. First, we only had access to published material from the included studies. Second, in many of the included studies it was not possible to determine whether patients were consecutively included or not. This, in combination with many of the studies being retrospective, leads to a risk of publication bias. Most of the present studies contained few BM patients, and did not have sufficient strength or the right study design to clarify which factors increase the risk of BM, or which factors are prognostic. Furthermore, the literature and quality of studies regarding efficacy treatment for BM from CRC are sparse, making recommendation in this regard unreliable. This review highlight the need for new studies about BM. Especially regarding treatment for BM from CRC.

4. Conclusion {#sec0016}
=============

The literature written about BM from CRC is sparse and heterogeneously designed studies make firm conclusion difficult. BM in patients with CRC are relatively uncommon disease manifestation, which occurs in 3--7%. It was not possible to detect an increase in incidence of BM from CRC and study heterogeneity made conclusions uncertain. The most well established risk factors for BM are rectal cancer, having lymph node invasion at surgery of primary tumor, and lung metastases at any time. Other risk factors have been suggested but results are not conclusive. Survival ranges from 5 to 21 months after diagnosis of BM in included studies depending on cohort. Several variables have been suggested as potential prognostic markers but are all poorly investigated. Treatments of BM are not well investigated though patients seem to benefit from bisphosphanate treatment with regard to lower risk of skeletal related events.

This review highlight the need for new studies about BM from CRC.
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[^1]: *Abbreviations*: BM = Bone metastases. CRC = colorectal cancer, mCRC = metastatic colorectal cancer, CC= colon cancer, RC= rectum cancer, T = tumor size, N = lymph node status, M = distant metastases, HAI = Hepatic artery chemo infusion.

[^2]: Only initial site of metastases.

[^3]: 5 year survival: BM and other metastases 16%, BM only 38%.

[^4]: Survival for patients with BM only.

[^5]: *Abbreviations*: CRC = Colorectal cancer, CEA = Carcinoembryonic antigen.

[^6]: If both univariate and multivariate analysis was performed, only multivariate analysis is presented.

[^7]: Multivariate analysis was performed but results of multivariate analysis only presented for RAS status where a positive association was identified.

[^8]: *Abbreviations*: SRE = Skeletal related events, CEA = Carcinoembryonic antigen.

[^9]: If both univariate and multivariate analysis was performed, only multivariate analysis is presented.

[^10]: *Abbreviations*: SRE = Skeletal related events, defined as pathologic fracture, spinal cord compression, radiation therapy to bone, change in antineoplastic therapy and surgery to bone, OS = Overall survival, NS = No significant association, BM = Bone metastases.

[^11]: Effect size not reported.
